A recent survey commissioned by our company across more than 50 small, mid-sized, and large biopharmaceutical companies worldwide, shed light on the key reasons why biotechs outsource their early biologic development and manufacturing to a CDMO. In this 20-min panel discussion, members of our End-to-End Solutions team, part of the BioReliance® portfolio, will offer their perspectives on what we heard from respondents.
We discuss major hurdles biotechs mentioned and how a customer-centric CDMO partnership can help overcome these, dismissing the idea of one-size-fits-all.
In this webinar, you will learn about:
- Top reasons to outsource to a CDMO
- Overcoming hurdles with a CDMO partnership
- What early-stage biotechs should look for in a CDMO
Speakers
Magali Toueille, Ph.D.
Merck
Downstream Process Development Manager
Magali Toueille, Ph.D., studied biological science and held various research positions in public institutes in France and Switzerland. She then joined Pall Life Sciences as senior manager of chromatography applications. Following this, she served as head of downstream process development at Genethon for five years. In 2020, she became downstream process development manager at Merck, for the CDMO business. She leads downstream process development for client and internal improvement projects, continuously optimizing purification processes and enhancing process development programs.
Celine Raymond, Ph.D.
Merck
Upstream Process Development Manager
Céline Raymond, Ph.D. is an upstream process development manager at our End-to-End Biodevelopment Center Martillac, France. She leads upstream process development activities for client projects as well as internal projects aimed at continuously optimizing the performance of our developments.
After studying chemical engineering and biochemistry in France and Canada, Céline joined our End-to-End Biodevelopment Center Martillac in 2015 as upstream scientist before taking on the role as the head of the department in 2019. Celine holds a Ph.D. in biochemistry.
Pharma and biopharma manufacturing
- Biologics and Biosimilars Characterization
Duration:45min
Language:English
Session 1:presented February 2, 2022
To continue reading please sign in or create an account.
Don't Have An Account?